Brevan Howard Capital Management’s Avalo Therapeutics AVTX Stock Holding History

Brevan Howard Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$288K	Buy	+19,321	New	+$302K	﹤0.01%	1650

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Brevan Howard Capital Management's AVTX Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Avalo Therapeutics (AVTX) in Q1 2026: 19,321 shares worth $288K. The stake represents ﹤0.01% of the portfolio and ranks #1650 among its holdings.

97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

Brevan Howard Capital Management held 19,321 shares of Avalo Therapeutics worth $288K as of Q1 2026.
Avalo Therapeutics was a new Brevan Howard Capital Management position in Q1 2026.
Avalo Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1650 holding.
97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.